NewsNovo
Repligen Corporation has completed its acquisition of BioLife Solutions, Inc., finalizing a transaction that converts BioLife into a wholly owned subsidiary of the Delaware-based bioprocess equipment maker.
The merger closed on October 6, 2026, pursuant to a Merger Agreement dated July 21, 2026, ending BioLife's independent existence as a public company on the Nasdaq Stock Market LLC.
Under the terms of the deal, each outstanding share of BioLife common stock converted into the right to receive 0.1442 shares of Repligen common stock and $11.25 in cash.
The transaction was structured through two simultaneous mergers: Bravo Merger Sub I, Inc., a wholly owned subsidiary of Repligen, merged with and into BioLife, with BioLife surviving as a direct subsidiary of Repligen.
Keep reading